BETA-2 score at 28 days after islet allogeneic transplantation in type 1 diabetes for predicting 5-year outcomes

Affiliations

¹ Islet Transplant Programme Scotland, Department of Islet Transplantation and Diabetes, Royal Infirmary of Edinburgh, BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh EH16 4TJ, UK; Edmonton Islet Transplantation Programme, University of Alberta, Edmonton, AB, Canada. Electronic address: shareen.forbes@ed.ac.uk.

Comment

Shareen Forbes. Lancet Diabetes Endocrinol. 2023 Jun.

. 2023 Jun;11(6):376-377.

doi: 10.1016/S2213-8587(23)00090-6. Epub 2023 Apr 24.

¹ Islet Transplant Programme Scotland, Department of Islet Transplantation and Diabetes, Royal Infirmary of Edinburgh, BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh EH16 4TJ, UK; Edmonton Islet Transplantation Programme, University of Alberta, Edmonton, AB, Canada. Electronic address: shareen.forbes@ed.ac.uk.

No abstract available

Conflict of interest statement

SF collaborates with, and receives funding from, Novo Nordisk, Cell Therapy Programme, Copenhagen, Denmark.

Association between primary graft function and 5-year outcomes of islet allogeneic transplantation in type 1 diabetes: a retrospective, multicentre, observational cohort study in 1210 patients from the Collaborative Islet Transplant Registry.
Chetboun M, Drumez E, Ballou C, Maanaoui M, Payne E, Barton F, Kerr-Conte J, Vantyghem MC, Piemonti L, Rickels MR, Labreuche J, Pattou F; Collaborative Islet Transplant Registry (CITR) Investigators study group. Chetboun M, et al. Lancet Diabetes Endocrinol. 2023 Jun;11(6):391-401. doi: 10.1016/S2213-8587(23)00082-7. Epub 2023 Apr 24. Lancet Diabetes Endocrinol. 2023. PMID: 37105208 Free PMC article.